Maintenance fees coming due
58 maintenance fees come due in the 12 months from Nov 16, 2026, the next on Nov 30, 2026. Unpaid by Jun 1, 2027, that one lapses early.
A maintenance fee does not end a patent on its due date. It falls due at 3.5, 7.5
and 11.5 years from grant, and the patent lapses only if the fee is still unpaid at the end of the
six month grace period that follows.
| Patent | Title | Holder | Status | Fee due | Lapses if unpaid | Expires | Confidence |
|---|---|---|---|---|---|---|---|
| US 11,660,297 | Antiproliferative Compounds and Second Active Agents for Combined Use In force Fee due Nov 30, 2026 Lapses if unpaid Jun 1, 2027 · High confidence | Celgene Corporation | In force | Nov 30, 2026 | Jun 1, 2027 | High confidence | |
| US 11,660,302 | 3-(4-((4-(MORPHOLINOMETHYL-BENZYL)OXY)-1 -OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-Dione for the Treatment of Systemic Lupus Erythematosus In force Fee due Nov 30, 2026 Lapses if unpaid Jun 1, 2027 · High confidence | Celgene Corporation | In force | Nov 30, 2026 | Jun 1, 2027 | High confidence | |
| US 11,666,579 | Methods of Treating Hematological Malignancies Using 2-(2,6-Dioxopiperidin-3-YL)-4-((2-Fluoro-4-((3-Morpholinoazetidin-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-Dione In force Fee due Dec 6, 2026 Lapses if unpaid Jun 7, 2027 · High confidence | Celgene Corporation | In force | Dec 6, 2026 | Jun 7, 2027 | High confidence | |
| US 9,051,110 | Packaging for Medicine for Clinical Trials or Commercial Use In force Fee due Dec 9, 2026 Lapses if unpaid Jun 9, 2027 · High confidence | Celgene Corporation | In force | Dec 9, 2026 | Jun 9, 2027 | High confidence | |
| US 10,328,077 | Treatment of Relapsed And/Or Refractory Solid Tumors and Non-Hodgkin's Lymphomas In force Fee due Dec 25, 2026 Lapses if unpaid Jun 25, 2027 · Medium confidence | Celgene Quanticel Research, Inc. | In force | Dec 25, 2026 | Jun 25, 2027 | Medium confidence | |
| US 10,335,495 | Biomolecule Conjugates In force Fee due Jan 2, 2027 Lapses if unpaid Jul 2, 2027 · High confidence | Celgene Corporation | In force | Jan 2, 2027 | Jul 2, 2027 | High confidence | |
| US 10,338,077 | Methods for Determining Drug Efficacy for Treatment of Cancer Using Ratios of Cereblon Associated Proteins In force Fee due Jan 2, 2027 Lapses if unpaid Jul 2, 2027 · High confidence | Celgene Corporation | In force | Jan 2, 2027 | Jul 2, 2027 | High confidence | |
| US 11,701,362 | Compositions and Methods of Use of CIS-4-[2-{[(3S,4R)-3-Fluorooxan-4-YL]AMINO}-8-(2,4,6-Trichloroanilino)-9H-PURIN-9-YL]-1-Methylcyclohexane-1-Carboxamide In force Fee due Jan 18, 2027 Lapses if unpaid Jul 19, 2027 · Low confidence | Celgene Corporation | In force | Jan 18, 2027 | Jul 19, 2027 | Low confidence | |
| US 10,357,489 | Antiproliferative Compounds and Methods of Use Thereof In force Fee due Jan 23, 2027 Lapses if unpaid Jul 23, 2027 · High confidence | Celgene Corporation | In force | Jan 23, 2027 | Jul 23, 2027 | High confidence | |
| US 9,096,573 | 6-, 7-, or 8-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same In force Fee due Feb 4, 2027 Lapses if unpaid Aug 4, 2027 · High confidence | Celgene Corporation | In force | Feb 4, 2027 | Aug 4, 2027 | High confidence | |
| 48 more maintenance fees coming due in the 12 months from Nov 16, 2026 · Pro | |||||||
10 of 58 patents shown. Soonest fee due date first, then patent number.
Pro members see every patent with a maintenance fee coming due: number, title, status, the due date, and the date it lapses if the fee goes unpaid through the grace period.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.